Obesity as a Systemic Disease

Obesity is now recognized as a systemic disease with widespread effects on metabolic and cardiovascular health. Excessive fat accumulation promotes chronic inflammation, insulin resistance, and endothelial dysfunction, contributing to the accumulation of risk factors known as metabolic syndrome (MetS).^1–3 MetS significantly increases the risk of type 2 diabetes, hypertension, atherosclerotic cardiovascular disease, and heart failure.⁴ In this issue of the Journal, Nishikawa et al. demonstrate that even modest weight loss over 1 year was associated with MetS resolution in participants of Japan’s Specific Health Guidance (SHG) program.⁵ This finding underscores the clinical significance of achievable weight management goals.

Article p 909

Using a large health examination cohort in a retrospective study, Nishikawa et al. found that even modest weight changes over 1 year were associated with improved metabolic status and increased probability of MetS resolution. This finding suggests that achievable, incremental weight loss goals, more realistic than the guideline-recommended 5–10% reduction target, can yield measurable metabolic benefits in routine preventive care. Recent studies published in Circulation Reports also focus on metabolic and obesity-related pathophysiology. One study reported a novel mitochondrial formulation that suppresses visceral fat inflammation in an obese mouse model, substantiating the mechanistic link between adipose tissue dysfunction and metabolic disease progression.⁶ Furthermore, research on the clinical phenotypes of obesity in a cohort of acute heart failure patients has highlighted the complexity of metabolic risk in cardiovascular disease patients.⁷ Taken together, these studies illuminate the interconnected pathways through which obesity affects systemic health.

Adipose tissue is not merely a fat reservoir but an endocrine organ that secretes cytokines and adipokines regulating systemic metabolism.^1,2 Visceral fat accumulation promotes systemic inflammation and insulin resistance, which in turn exacerbates dyslipidemia, hypertension, and endothelial dysfunction, the core processes of MetS. These mechanisms extend beyond metabolic markers to affect multiple organ systems.⁸ (1) The cardiovascular system: Obesity accelerates atherosclerosis and contributes to heart failure, particularly in heart failure with preserved ejection fraction, via hemodynamic load and metabolic stress. (2) The renal system: Excess fat accumulation correlates with chronic kidney dysfunction through glomerular injury and inflammatory processes. (3) Cerebrovascular risk: Metabolic abnormalities contribute to stroke risk via vascular and microvascular dysfunction.

Furthermore, the deleterious effect of obesity is evident in recent research published in the Circulation Journal. A recent analysis of the JROAD/JROAD-DPC database showed that high BMI in cardiovascular surgery patients correlated with increased hospital-related complications and healthcare burden, underscoring obesity’s broad systemic effects (Figure).⁹ Beyond adulthood, findings on pediatric MetS components and cutoff values highlight that metabolic risk begins in childhood, further underscoring obesity’s lifelong burden.¹⁰

Figure.

Systemic effects of obesity, and pathways to metabolic improvement with weight reduction. Excess adiposity, particularly visceral fat, drives systemic inflammation, insulin resistance, endothelial dysfunction, and neurohormonal activation. These mechanisms contribute to the development of metabolic syndrome (MetS), type 2 diabetes, hypertension, atherosclerotic disease, heart failure, kidney dysfunction, and cerebrovascular disease. Weight reduction attenuates these pathways, leading to improvements in metabolic parameters and reductions in cardiometabolic risk across organ systems.

The real-world results from Nishikawa et al. provide actionable evidence for preventive counseling: promoting incremental weight loss of 2% or 3% can significantly improve metabolic profiles and contribute to MetS resolution.⁵ For clinicians, this supports a shift away from insisting solely on ambitious weight loss goals toward recognizing the value of achievable, stepwise targets.

Lifestyle interventions remain central to weight management. Systematic reviews of lifestyle interventions show structured programs can induce sustained MetS remission, though optimal long-term effects may require combination with pharmacotherapy.¹¹ Therefore, integrated strategies combining achievable weight loss goals with behavioral support may offer the most practical benefits in primary care and preventive medicine settings.

The public health burden of obesity and MetS continues to rise globally. The increasing prevalence of metabolic risk factors across societies heightens concerns about the future burden of cardiovascular disease. Although large-scale strategies targeting dietary improvement, physical activity promotion, and early screening are crucial, evidence that even modest weight loss leads to metabolic improvements at the population level provides a rationale for advancing prevention policies and awareness campaigns.

In conclusion, Nishikawa et al. demonstrate that modest weight loss in SHG participants was associated with significant metabolic improvements and an increased rate of MetS resolution. These findings reinforce the concept of obesity as a systemic disease and underscore the clinical significance of achievable weight loss goals in preventive cardiometabolic care.

Conflict of Interest

T.H. declares no conflicts of interest.

Disclosures

T.H. is a member of Circulation Reports’ Editorial Team.

IRB Information

None.

Funding Statement

Funding Statement: Sources of Funding: This work was partially supported by a JSPS Kakenhi Grant (Number 23K15132 to T.H.). The funder had no role in the study design, data collection and analysis, or manuscript preparation.